FDA Approves Protagonist and Takeda's Mimrylo for Polycythemia Vera
Source Summary
The FDA has approved Mimrylo, a new treatment developed jointly by Protagonist and Takeda for polycythemia vera, a rare blood cancer. Mimrylo represents a new class of therapy for this condition.
Why it matters
FDA approval of a novel therapeutic class expands treatment options for patients with polycythemia vera, a previously limited-choice rare blood cancer.
